News and Press Releases
Antibiotics | Advocacy CF Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

| 2 min read
Research | Antibiotics | About the CF Foundation CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.

| 3 min read
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

| 4 min read